Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Related to this article
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
2
Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD
3
Phase 1 Clinical Studies Completed: NTX-253 for the Treatment of Schizophrenia
4
Measurement-Informed Psychiatric Care: If Not Now, Then When?
5